1,2-Pentanediol | CAS:5343-92-0

We serve 1,2-Pentanediol CAS:5343-92-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1,2-Pentanediol

Chemical Name: 1,2-Pentanediol
CAS.NO:5343-92-0
Synonyms:PENTANDIOL-1,2
PTD
Pentane-1,2-Diol
propylethylene glycol
1,2,pentandiol
 
Molecular Formula:C5H12O2
Molecular Weight:104.14800
 
Physical and Chemical Properties:
Density:0.971 g/mL at 25 °C(lit.)
Boiling point:206 °C(lit.)
Melting point:/
Flash point:104 °C
Index of Refraction:1.439
 
Specification:
Appearance:Pure colorless to light yellow liquid
Purity:≥99.0%
 
Packing:15 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 1,2-Pentanediol is used in synthesizing quinoxalines from biomass-derived glycols. Also used in the synthesis of propiconazole a fungicide as well as other antifungals.Cosmetic raw materials



Contact us for information like 1,2-Pentanediol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,2,pentandiol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pentane-1,2-Diol Use and application,PTD technical grade,usp/ep/jp grade.


Related News: Here’s what we can tell you so far:(R)-[N-3-(3-fluoro-4-morpholinylphenyl)-2-oxo-5-oxazolidinyl]methyl azide manufacturer Here’s what we can tell you so far:Cordycepin supplier Here’s what we can tell you so far:1,4,7,10-tetrabenzyl-1,4,7,10-tetrazacyclododecane vendor The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy.